Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8Neoplasm Metastasis 3Neoplasms 2Carcinoma, Pancreatic Ductal 2Adenocarcinoma 2Thromboembolism 1Stomach Neoplasms 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Adenocarcinoma 1Metastatic Pancreatic Adenocarcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 6Fluorouracil 5Leucovorin 4Irinotecan 3Albumin-Bound Paclitaxel 3pembrolizumab 2irinotecan sucrosofate 2Oxaliplatin 24-fluorobenzoyl-TN-14003 2zolbetuximab 1regorafenib 1olaparib 1ibrutinib 1beta-D-glucosylisophosphoramide mustard 1adavosertib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1PEGPH20 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Adenocarcinoma × PEGPH20 × Clear all
NCT01959139 2024-02-09

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

SWOG Cancer Research Network

Phase 1/2 Completed
126 enrolled 19 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡